ADMA Biologics Q2 2026 Earnings: ASCENIV Mix Drives Margin Expansion

ADMA Biologics (Nasdaq: ADMA) reported Q2 2026 revenue of $124.4 million, up 2% from $122.0 million a year earlier, while diluted EPS increased to $0.16 from $0.14. For the quarter ended June 30, gross margin expanded to 69% from 55% as higher-margin ASCENIV represented a larger share of sales and the company benefited from its yield-enhanced manufacturing process. ADMA also reiterated its FY2026 financial guidance.

Core Results

The modest increase in total revenue masked a significant change in product mix. Gross profit rose 28% and operating income increased approximately 23%, but higher operating expenses and a higher effective tax rate limited GAAP net income growth to 11%.

Adjusted EBITDA increased 22% to $61.8 million, substantially faster than revenue, reflecting the improvement in product economics.

Adjusted net income and adjusted EBITDA are non-GAAP measures. Basic EPS, which the company highlighted separately, increased to $0.17 from $0.14.

Business and Product Performance

ASCENIV generated approximately 83% of total quarterly revenue and remained ADMA’s principal growth driver. Its $19.6 million year-over-year revenue increase largely offset the $18.3 million decline in BIVIGAM, leaving total company revenue only $2.4 million higher.

Management attributed ASCENIV’s performance to increased physician adoption, broader prescriber engagement, new patient starts and higher utilization. June produced the strongest sequential monthly utilization growth since the first half of 2024.

BIVIGAM remained the principal drag on revenue, although management said utilization and revenue improved sequentially from their Q1 2026 trough. No specific sequential revenue figure was provided.

ASCENIV Mix Lifted Operating Profit, but Taxes and Spending Limited Net-Income Growth

Cost of product revenue declined to $38.1 million from $54.8 million even as total revenue increased. The resulting gross-margin expansion reflected the shift toward higher-margin ASCENIV and continuing benefits from the yield-enhanced manufacturing process approved in 2025.

Some of that benefit was absorbed by investment and overhead. Research and development expense rose to $6.0 million from $1.0 million, primarily because of SG-001 development. Selling, general and administrative expense increased to $26.7 million from $22.2 million due to employee costs, software maintenance, professional and consulting fees connected with legal matters, and corporate growth initiatives.

The effective tax rate also increased to 24.7% from 14.7%. As a result, the tax provision more than doubled to $12.4 million, helping explain why net income grew more slowly than operating income and adjusted EBITDA.

Cash Flow, Balance Sheet and Capital Allocation

ADMA did not provide quarterly cash flow, but operating cash flow for the first six months of 2026 increased to $87.8 million from $1.5 million in the comparable 2025 period. Net income growth and a $20.2 million cash benefit from lower accounts receivable supported the improvement, while inventory used $32.8 million of cash.

Cash and equivalents increased to $136.0 million at June 30 from $87.6 million at the end of 2025. Inventory rose to $239.3 million from $206.5 million, while accounts receivable declined to $138.2 million from $158.4 million.

Total current and long-term debt increased to approximately $196.6 million from $72.1 million at year-end, reflecting $125.0 million of proceeds from the JPM revolving facility. ADMA used $155.2 million to acquire treasury stock during the first half. It repurchased approximately 7.1 million shares during Q2 and 13.8 million shares through June 30, equal to 5.3% of common shares outstanding, and maintained its target of at least $200 million in 2026 repurchases.

FY2026 Guidance

ADMA reiterated all three of its FY2026 guidance ranges. Management said the outlook continues to account for sustained competition and pricing pressure in the U.S. immune globulin market through the rest of the year, with ASCENIV expected to remain the main growth driver.

The adjusted net income and adjusted EBITDA guidance is presented on a non-GAAP basis, and the company did not provide corresponding GAAP reconciliations because certain potential adjustments could not be reasonably estimated.

Management Commentary

Management emphasized ASCENIV’s growing use among later-line, refractory and medically complex primary immunodeficiency patients. ADMA analyzed 127 real-world ASCENIV-treated patients, most of whom had previously received other immune globulin therapies. The company reported statistically significant reductions after ASCENIV initiation in infection-related hospitalizations, outpatient healthcare use, oral antibiotic use and corticosteroid use, along with a decline in the proportion of patients experiencing infection-related emergency-room visits.

The findings were submitted as an abstract to the November 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting. ADMA believes the evidence could support physician adoption, payer access and utilization, although those commercial effects have not yet been quantified.

For SG-001, ADMA plans to conduct conformance-lot production during the second half of 2026 and expects to submit a pre-Investigational New Drug meeting package to the FDA by year-end. The program remains preclinical and was the primary reason for the quarter’s higher R&D spending.

Recent Insider Transactions

The supplied six-month insider summary classified 668,926 shares across 18 transactions as purchases and 52,096 shares across three transactions as sales, resulting in net purchases of 616,830 shares. The latest reported transactions also included stock grants, gifts and derivative-security exercises, so they should not all be treated as open-market trading.

The values below are transaction values reported in the supplied data, not share counts. All ten transactions were reported as direct holdings.

These transactions provide an objective record of insider activity but do not, by themselves, establish management’s view of ADMA’s valuation or future performance.

Risks Investors Need to Watch

• Dependence on ASCENIV: ASCENIV accounted for approximately 83% of Q2 revenue. Slower adoption, utilization or payer access would therefore have an outsized effect on company-wide growth and margins.
• BIVIGAM weakness and market pricing: BIVIGAM revenue remained 48.5% below the prior-year period. ADMA’s guidance also incorporates continued competition and pricing pressure in the U.S. immune globulin market.
• Rising expenses and taxes: Higher R&D and SG&A spending, together with the increase in the effective tax rate, caused net income to grow more slowly than gross profit and operating income.
• Capital allocation and leverage: Cash generation improved, but total debt rose materially and first-half treasury-stock purchases used $155.2 million. Continued repurchases, inventory investment and pipeline spending will depend on sustained operating cash generation.
• SG-001 execution: The program remains preclinical. Its planned manufacturing and regulatory milestones could require additional spending before any commercial contribution.

Summary

ADMA’s Q2 2026 results were defined by a mix shift rather than broad-based revenue growth. ASCENIV’s expansion nearly offset the continuing BIVIGAM decline and produced substantially higher gross margin, operating income and adjusted EBITDA, while higher expenses and taxes moderated net-income growth. The main items to monitor are whether ASCENIV utilization continues to accelerate, whether BIVIGAM’s sequential stabilization persists, and whether operating cash flow remains sufficient to support inventory, pipeline development and the company’s repurchase plan while meeting unchanged FY2026 guidance.

Find out more